EXTON, PA — In a move that strengthens its position as a global leader in innovative solutions for injectable drug administration systems, West Pharmaceutical Services, Inc. (NYSE: WST) recently announced the FDA 510(k) clearance and launch of its Vial2Bag Advanced® 13mm admixture device.
The latest addition to West’s portfolio complements the existing Vial2Bag Advanced® 20mm admixture device. These two products provide versatile options for reconstituting and transferring drugs using either a 13mm or 20mm vial and an IV bag prior to patient administration. The new device is needle-free and boasts a dual channel design that provides dedicated fluid pathways into and out of the IV bag. It also features a robust vial spike design for secure connection to the drug vial.
Cindy Reiss-Clark, Chief Commercial Officer at West, spoke about the significance of the product launch. “This year, West celebrates 100 years as an industry leader and scientific innovator in high-quality injectable solutions,” said Reiss-Clark. “The 13mm product is a key addition to our administration system portfolio, addressing the critical need for more drug preparation and delivery options at the point-of-care.”
The official launch of the Vial2Bag Advanced® 13mm admixture device took place at Progressive Medical Inc’s Booth #500 at the American Society of Health-System Pharmacists Midyear Clinical Meeting, which ran from December 3 through 7 in Anaheim, CA.
West Pharmaceutical Services finished strong on Friday, December 8, 2023, closing at $342.24, an increase of $1.05 (0.31%). The company’s 52-week high stands at $415.73. This new product launch, backed by FDA clearance, is expected to bolster West’s position in the market, offering a wider range of solutions for injectable drug administration.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.